"Antibody therapies for severe gastrointestinal diseases"



Calypso Biotech SA, based in Geneva, Switzerland, is a biopharmaceutical company, spin-off from Merck Serono, focused on developing antibody therapies up to clinical proof-of-concept for the treatment of diseases with large unmet medical needs. 

Calypso Biotech's vision is to give new hope to patients suffering from severe gastro-intestinal diseases such as gastric and pancreatic cancer, inflammatory bowel disease or refractory celiac disease by restoring their health and quality of life.

Our portfolio consists of two preclinical therapeutic antibodies that intercept key immune checkpoints in the gastro-intestinal tract.